V600EBRAF突变转移性结直肠癌经验证的预后分类器:BRAF BeCool研究
该研究基于22家机构的两大回顾性V600EBRAF突变mCRC系列,构建并内外部验证预后评分。探索集395例中,体能状态、CA19.9、LDH、中性粒/淋巴细胞比值、分级及肝肺淋巴结受累为OS独立预后因素,完整评分低、中、高危中位OS分别为29.6、15.5和6.6个月。
要点
- 完整评分含实验室指标,低中高危中位OS分别为29.6、15.5、6.6个月。
- 简化评分仅用临床病理变量,外部验证获得确认。
- 评分基于易采集数据,可用于临床分层和临床试验患者选择。
核心结论
- 基于易采集数据的评分系统可区分V600EBRAF突变mCRC不同预期寿命亚组。
- 该工具可用于临床实践、临床试验分层及探索性转化分析调整。
研究设计与样本
- 回顾性研究,22家机构的两大V600EBRAF突变mCRC系列分别作为探索集和验证集。
- 探索集共395例V600EBRAF突变mCRC,模型进行内部和外部验证。
主要发现
- 探索集多因素分析显示体能状态、CA19.9、LDH、中性粒/淋巴细胞比值、分级及肝、肺、淋巴结受累为OS独立预后因素。
- 完整评分(0-16)低(0-4)、中(5-8)、高(9-16)危患者比例分别为44.7%、42.6%、12.6%。
- 完整评分低、中、高危中位OS分别为29.6、15.5、6.6个月;中危vs低危HR 2.16(95%CI 1.44-3.22,p<.001),高危vs低危HR 4.72(95%CI 2.72-8.20,p<.001)。
- 调整一线治疗类型及采用简化评分后观察到相似结果。
- 简化评分在验证集中进行外部确认。
关键数值与推荐
- 完整评分含所有显著协变量(0-16分),简化评分仅含临床病理协变量(0-9分)并排除实验室值。
- 完整评分风险分组:低危0-4分,中危5-8分,高危9-16分。
临床怎么用
- 可用于V600EBRAF突变mCRC患者预后分层,辅助临床决策。
- 可在临床试验中用于患者分层和探索性转化分析调整。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the well-known negative prognostic value of the V600EBRAF mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous, and the basis for this prognostic heterogeneity should be better defined. METHODS: Two large retrospective series of V600EBRAF-mutated mCRC from 22 institutions served as an exploratory and validation set to develop a prognostic score. The model was internally and externally validated. RESULTS: A total of 395 V600EBRAF-mutated mCRCs were included in the exploratory set. Performance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and liver, lung and nodal involvement emerged as independent prognostic factors for overall survival (OS). Two different scoring systems were built: a 'complete' score (0-16) including all significant covariates and a 'simplified' score (0-9), based only on clinicopathological covariates, and excluding laboratory values. Adopting the complete score, proportions of patients with a low (0-4), intermediate (5-8) and high (9-16) score were 44.7%, 42.6% and 12.6%, respectively. The median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk: 2.16, 95% confidence interval [CI]: 1.44-3.22, p < .001) and 6.6 months (HR for high vs low risk: 4.72, 95% CI: 2.72-8.20, p < .001). Similar results were observed also after adjusting for the type of first-line treatment and adopting the simplified score. The simplified prognostic score derived from the exploratory set was then applied to the validation set for external confirmation. CONCLUSIONS: These scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy. These tools could be useful in clinical practice, would allow better stratification of patients in clinical trials and may be adopted for proper adjustments in exploratory translational analyses.
引用
- Loupakis F, Intini R, Cremolini C, et al. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. Eur J Cancer. 2019. PMID: 31330487. doi:10.1016/j.ejca.2019.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。